Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prescription drug dispensations 15 years before multiple sclerosis onset: A matched cohort study, British Columbia, Canada.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same author

Phenotyping healthcare use before pediatric-onset multiple sclerosis, including by sex and age: A matched cohort study.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same author

Impact of cancer on multiple sclerosis-related healthcare and disease-modifying drug use: A multinational cohort study.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same author

Sex-related and age-related differences in healthcare use before multiple sclerosis symptom onset: a matched cohort study.

Journal of neurology, neurosurgery, and psychiatry·2026
Same author

A susceptibility network analysis of disease trajectories leading to multiple sclerosis: A nationwide cohort study.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same author

Setting priorities for how future research in multiple sclerosis in Canada considers equity, diversity and inclusion: A modified e-Delphi study.

Multiple sclerosis journal - experimental, translational and clinical·2026

Related Experiment Video

Updated: Nov 20, 2025

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool
11:35

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool

Published on: June 30, 2014

58.4K

A multiple sclerosis disease progression measure based on cumulative disability.

Ali Manouchehrinia1, Elaine Kingwell2, Feng Zhu2

  • 1Department of Clinical Neuroscience, Karolinska Institutet, Karolinska University Hospital Solna, Stockholm, Sweden.

Multiple Sclerosis (Houndmills, Basingstoke, England)
|January 25, 2021
PubMed
Summary

A new metric, the normalized Age-Related MS Severity Score (nARMSS), reliably summarizes multiple sclerosis (MS) disease progression. This tool enables accurate longitudinal comparisons of MS severity between patients.

Keywords:
Multiple sclerosisdisabilityoutcomeprogression measure

More Related Videos

Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis
08:11

Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis

Published on: November 14, 2016

11.3K
A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
10:46

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data

Published on: December 9, 2015

10.8K

Related Experiment Videos

Last Updated: Nov 20, 2025

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool
11:35

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool

Published on: June 30, 2014

58.4K
Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis
08:11

Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis

Published on: November 14, 2016

11.3K
A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
10:46

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data

Published on: December 9, 2015

10.8K

Area of Science:

  • Neurology
  • Clinical Research
  • Biostatistics

Background:

  • Current multiple sclerosis (MS) severity measurements are predominantly cross-sectional.
  • This limitation hinders longitudinal tracking and comparison of individual disease courses.

Purpose of the Study:

  • To develop a novel severity metric for multiple sclerosis (MS).
  • The metric aims to reliably summarize a patient's disease progression over time.

Main Methods:

  • Developed the normalized Age-Related MS Severity Score (nARMSS).
  • nARMSS integrates deviations from expected scores over follow-up time.
  • Metric scales from -5 to +5, with positive values indicating a more severe disease course.

Main Results:

  • nARMSS demonstrated high predictive accuracy in Swedish MS registry data (AUC-ROC 0.929-0.941).
  • External validation in a Canadian cohort confirmed its efficacy (AUC-ROC 0.901-0.908).
  • The metric effectively predicts the most severe quartile of disease course.

Conclusions:

  • nARMSS offers a reliable and generalizable method for assessing MS severity.
  • Facilitates feasible longitudinal comparisons of disease progression between individuals.
  • Provides an easily measurable tool for clinical and research applications.